We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Veravas and MIP Diagnostics Announce Agreement for Improved Diagnostics

Veravas and MIP Diagnostics Announce Agreement for Improved Diagnostics content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Veravas, Inc., a diagnostic company focusing on sample preparation products and new diagnostic tests and MIP Diagnostics Ltd., the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, have announced that they have entered into a mutually beneficial agreement for the development, license, and supply of a novel MIP specific for Veravas’ proprietary sample preparation technology.

Veravas is aiming to target two key issues within the field of diagnostics. The first is the widespread issue of diagnostic interferences – substances like biotin that alter routine test results. The second is the difficulty in measuring biomarkers of low abundance.

The combination of Veravas’ sample preparation technology and MIP Diagnostics technology and manufacturing capabilities in Molecularly Imprinted Polymers (MIPs) is intended to result in the creation of novel products to help diagnostic companies manage risks associated with troublesome interferences in current test designs. The long-term benefits of this collaboration could have significant impact over existing methods.

“This new strategic relationship with MIP Diagnostics will allow Veravas to complete its biotin ecosystem of products and support IVD manufacturers in designing and developing assays that are minimally affected by biotin and other common heterophilic interferences,” said Carroll E. Streetman Jr., CEO, Veravas. “We consider this to be a valuable alliance as the combination of our two technologies supports Veravas’s efforts to bring novel diagnostic tests to market in the fields of neuroscience, bone and mineral metabolism, and cardiology.”